Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Byetta Prescribers for Diabetes: Endocrinologists

Council Members in this Study Group: 150

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Harold Bays, President and Medical Director, L-MARC Research CenterHarold Bays

President and Medical Director
L-MARC Research Center
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Harold Bays, MD, FACP, FACE, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all...

Dan Streja

Clinical Professor of Medicine
UNIVERSITY OF CALIFORNIA, LOS ANGELES
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA...

1 news post(s)
Farhad Zangeneh, Assistant Clinical Professor of Medicine , THE GEORGE WASHINGTON UNIVERSITY - CCFarhad Zangeneh

Assistant Clinical Professor of Medicine
THE GEORGE WASHINGTON UNIVERSITY - CC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Farhad Zangeneh, MD, is an Assistant Clinical Professor of Medicine at George Washington University School of Medicine in District of Columbia. He is on the board of directors of ACCE and recently contributed to the AACE Diabetes guidelines. He is the...

George Griffing

Director of General Internal Medicine
SAINT LOUIS UNIVERSITY
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

George Griffing, MD, is Professor of Internal Medicine at St. Louis University. Dr. Griffing's clinical expertise includes the diagnosis and treatment of diabetes. His research interests include the clinical investigation of inhaled insulin, nasal insulin...

Michael Dempsey, Medical Director, SUBURBAN HOSPITAL, INCMichael Dempsey

Medical Director
SUBURBAN HOSPITAL, INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Michael Dempsey, MD, is a Private Practitioner in Rockville, Maryland. He is the Medical Director of the Johns Hopkins Diabetes Center at Suburban Hospital, where he is also the Medical Director of Diabetes Education and Endocrine Subsection Chair. He...

1 news post(s)

View all Leading Experts in this Study Group

GLG NewsSM Analyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Another Glinide: Where's the Beef?

March 28, 2008

Analysis by:Joseph Bass, Associate Professor of Medicine and Neurobiology,

Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug | www.pipelinereview.com

Elixir has turned to a strategy devoid of innovation by selecting a combination glinide (metiglinide) plus glucophage for treatment of type 2 diabetes.  With the new availability of DPP4 inhibitors (sitagliptin/alogliptin) and incretin agonists (eg byetta), what is the prospect of another K channel antagonist.  The old problems likely will still appear: hypoglycemia, weight gain, and possibly progression of pancreatic failure/cell death.

Warning on A1C Targets and Diabetes Death in ACCORD Trial

February 8, 2008

Analysis by:Joseph Bass, Associate Professor of Medicine and Neurobiology,

Hault of ACCORD Study Intensive Treatment Arm | www.nhlbi.nih.gov

Increased death from intensive A1C lowering in diabetic subjects raises new concerns about diabetes therapy, insulin use in combination with oral agents, and clinical biomarkers of disease complications.

Predicting Winners in Oral Diabetes Competition: Galvus, Alogliptin & Januvia

February 5, 2008

Analysis by:Joseph Bass, Associate Professor of Medicine and Neurobiology,

Galvus(R), A New Treatment For Patients With Type 2 Diabetes, Receives European Approval For Label Update Paving The Way For EU Launches | www.pipelinereview.com

Oral therapies improve complianceEU approval of Galvus does not erase US doubts

Outsourcing of compassionate use of drugs?

January 18, 2008

Analysis by:Dan Streja, Clinical Professor of Medicine,

No right to experimental drugs for dying patients: Supreme Court | news.yahoo.com

The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal illness have traveled outside the US to purchase hope when our management was offering none. Although in the majority of cases the hope was unjustified, the current decision will encourage healthcare providers residing outside the US to advertise for their services through the internet. The issue should be addressed by the legislators sooner rather than later. Drugs who improve quality of life, awaiting approval for survival indication or drugs looking promising in early clinical trials could be made available to dying patients with informed consent addressing our limitations.  

Alogliptin on the diabetes horizon.

January 9, 2008

Analysis by:Joseph Bass, Associate Professor of Medicine and Neurobiology,

Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. | www.pipelinereview.com

Diabetes is on the rise globallyExisting oral therapeutics have significant drawbacks but are cheap (generic) and some have been in use for many years.

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Private/For-Profit Healthcare Research Entity
  • Government/Military Hospital or Clinic

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Physician - Director
  • Owner
  • Partner
  • President
  • Director
  • Physician - Division Head
  • Physician - Department Chair

Related Study Groups

Study Group Name No. Members
Byetta Prescribers for Diabetes 261
Byetta Prescribers for Diabetes: Endocrinologists (US) 126
Endocrinologists (US) 633
Byetta Prescribers for Diabetes (US) 229
Diabetologists that Treat Type II Diabetes (US) 172
Physicians who Treat Diabetes (US) 466
Diabetologists (US) 258
Exubera Prescribers 111